Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by newbie101abcon Sep 26, 2024 8:46pm
47 Views
Post# 36243329

Found the link to

Found the link to the full report, you can download the PDF for free.   Just started reading it and already found this very interesting from page 3.   https://nap.nationalacademies.org/catalog/27766/cannabis-policy-impacts-public-health-and-health-equity    Also, Yasmin Hurd, Mt Sinai is one of the co-chairs.  Recall reading an old post by someone mentioning her and a clinical trial that this company is involved with her?   Have to finish reading the report.  See you in a few days, lol. 

The Food
and Drug Administration could approve medical use of a botanical cannabis
product by prescription, through its drug approval process, but it is
unclear whether that will happen. The impact on state cannabis programs
remains unclear, as does the impact on public health.
STUDY CHARGE AND APPROACH
The need for a comprehensive public health review of cannabis policy
prompted the Centers for Disease Control and Prevention (CDC) and the
National Institutes of Health to commission the National Academies of
Sciences, Engineering, and Medicine to convene an ad hoc committee charged
with describing cannabis and cannabinoid availability in the United States;
<< Previous
Bullboard Posts